Navigation Links
The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
Date:7/23/2008

- Nexavar is First Approved Systemic Therapy to Treat the Disease -

WAYNE, N.J. and EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that The New England Journal of Medicine published results of a Phase 3 trial demonstrating that Nexavar(R) (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo. This represents a 44 percent improvement in median overall survival for patients treated with Nexavar.

Based on the strength of these data, Nexavar was approved for HCC by the European Agency for the Evaluation of Medicinal Products (EMEA) and by the U.S. Food and Drug Administration (FDA) in October and November 2007, respectively.

"Despite advances in the management of many other cancers, liver cancer has remained a treatment challenge, due to a lack of systemic therapies to extend life and limited opportunity for surgical intervention," said Dr. Josep M. Llovet, co-principal investigator of the study and professor of research, Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clinic Barcelona; director of research, HCC Program, associate professor of Medicine, Mount Sinai School of Medicine, New York. "This landmark study reflects a new systemic standard of care using Nexavar in the first-line management of liver cancer."

"The number of lives lost to liver cancer continues to increase globally, due to the prevalence of hepatitis B and C infections," said Jordi Bruix, co-principal investigator and director of the Barcelona Clinic Liver Cancer (BCLC) Group; senior consultant, Liver Unit, Hospital Clinic of Barcelona. "We are encouraged that there is a new treatment option available for liver cancer that has clearly demonstrated a survival benefit in this patient population."

The in
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals,Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
2. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
3. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
4. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
5. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
6. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
7. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
8. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
9. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
(Date:8/20/2014)... August 20, 2014 The Workgroup ... nonprofit authority on the use of health IT ... the full agenda for its annual fall conference, ... Efficiency. WEDI-Con 2014 will take place at the ... 2014, attracting a diverse cross-section of payers, providers, ...
(Date:8/20/2014)... Doctors at the University of Hong Kong claim to ... mice by injecting them with a vaccine that changes their ... on its website. Click here to read the full ... Institute of Microbiology created a vaccine using a protein called ... the vaccine is designed to prevent mesothelioma cells from disabling ...
(Date:8/20/2014)... August 20, 2014 Today, Zane Benefits, ... on open enrollment for 2015. , According to Zane ... up in November, employees are encouraged to start thinking ... in 2015, the open enrollment period will run from ... enrollment 2015 individuals can purchase a new individual health ...
(Date:8/20/2014)... The report “Automotive Airbag and ... Global Analysis: by Geography - Trends and Forecasts ... defines automotive airbag and seatbelt market in terms ... growth opportunities in the coming years as well ... restrains, growth indicators, challenges, legislation trends, market dynamics, ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... ... Interim Leadership division as senior vice president. A seasoned executive with nearly 20 years of ... , ... 2009 -- B. E. Smith recently hired Deirdre Byrne to lead the firm’s ...
... , MIAMI, Dec. 17 Physicians Healthcare ... today announced that it has issued its financial statements for ... being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is a developer ...
... the employment and sociodemographic characteristics involved in the exposure of ... often work standing up or have to lift heavy objects, ... are frequently exposed to some physical risk in their place ... to exposure to workplace hazards", M Carmen Gonzlez, lead author ...
... PITTSBURGH, Dec. 17 Stem cells that could one day ... easily harvested from the tissue of the umbilical cord, just ... to treat some blood disorders, said University of Pittsburgh School ... the Journal of Biomedicine and Biotechnology . ...
... ... Online , ... Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun for Villanova’s newly online ... schedules can’t accommodate a campus-based program. With the university’s Master of Science in Human ...
... 17 CareFusion Corporation (NYSE: CFN ) announced today ... TRC Capital Corporation (TRC) to purchase up to four million shares ... of common stock outstanding. TRC,s offer price of $23.50 per share ... stock on Dec. 14, 2009, the last full trading day prior ...
Cached Medicine News:Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: